One Color
Black

Size: 15 X 13.6 cm

Danomond

Injection

Solution for injection

For vet use only

COMPOSITION:

Each 1 ml contains:

Danofloxacin 180 mg

(Eq. to 228.4 mg Danofloxacin mesylate)

PROPERTIES:

Danofloxacin is a synthetic fluoroquinolone antimicrobial agent that possesses potent in vitro activity against Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Escherichia coll.

The antimicrobial activity of danofloxacin is based upon the inhibition of microbial DNA gyrase and topoisomerase IV. The inhibitory effect is on the second step of the enzymatic process, uncoupling the breakage and reunion functions. Danofloxacin, in common with other fluoroquinolones, produces a stable complex between the enzyme and DNA. This results in the cessation of DNA replication and transcription. The bactericidal effect is also observed on bacteria in the stationary growth phase.

INDICATION:

Cattle:

In cattle: Treatment of bovine respiratory disease caused by Mannheimia haemolytica, Pasteurella multocida and Histophilus somni sensitive to danofloxacin. For the treatment of acute bovine mastitis caused by Escherichia coil sensitive to danofloxacin.

In neo-natal calves: Treatment of enteric infections caused by Escherichia coli sensitive to danofloxacin.

TARGET SPECIES:

Cattle.

DOSAGE OF ADMINISTRATION:

Route: Subcutaneously injection or intravenously.

For Whole Product:

1 ml / 30 kg body weight as a single injection by the subcutaneous or intravenous route,

If clinical signs of respiratory or enteric disease persist 48 hours after the first injection, an additional dose at 6 mg/kg body weight may be administered.

If clinical signs of acute bovine mastitis persist 36-48 hours after the first injection, the antibiotic

treatment strategy should be reviewed. It is recommended to treat animals in the early stages of disease and to evaluate the response to treatment within 36-48 hours.

WARNING & PRECAUTIONS:

- It is recommended to treat animals in the early stages of disease and to evaluate the response to treatment within 48 hours.
- When fluoroquinolones have been combined with bacteriostatic antimicrobials, such as tetracyclines and macrolides or phenicols, an antagonism was demonstrated in vitro.
- Use of fluoroquinolones should be based on susceptibility testing and take into account official and local antimicrobial use policies.
- Care should be taken to dose accurately and the product should be used with caution in animals with joint disease or cartilage growth disorders.
- Do not use with newly born pet animals.

CONTRAINDICATIONS:

- Do not use in cases of known hypersensitivity to the active ingredient, to other (Fluoro) quinolones or any ingredients product
- the use of the product not recommended for cows during pregnancy,
- Do not use cases where the pathogen involved is resistant to other fluoroquinolones (due to the potential or cross resistance }.
-Not co-adminstred with nor steroidal and inflamatory agents.

ADVERSE EFFECTS:

-In very rare cases in sensitive animals, immediate or delayed anaphylactic shock may occur after the injection.

- Subcutaneous injection of the product induces a moderate inflammatory response in the tissue around the injection site. The resultant lesions may persist for up to 30 days.

WITHDRAWAL TIME:

Meat and offal: 8 days

Milk: 4 days

STORAGE CONDITIONS :

store at temperature not exceeding 30°C and to be used after opening for 28 days at temperature not exceeding 30°C.

PACKAGING:

Transparent colorless glass vial (type II) containing 50,100ml solution, closed with chlorobutyl rubber stopper and non-reusable aluminum closures with label + insert leaflet

Manufactured by Eva Pharma for pharmaceuticals and medical appliances (Eva Pharma) for EVAPHARMA for Pharmaceutical industries (EVAPHARMA).

EVAPHARMA

HI129.00/00/00